Trial Profile
Phase II Study of Carboplatin+nab-Paclitaxel for Non-small Cell Lung Cancer with Interstitial Pneumonitis Study of evaluating SPARC expression
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Mar 2021
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Interstitial lung diseases; Non-small cell lung cancer
- Focus Pharmacodynamics
- 07 Jan 2015 New trial record